Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

48.05USD
16 Aug 2018
Change (% chg)

$1.40 (+3.00%)
Prev Close
$46.65
Open
$46.80
Day's High
$48.15
Day's Low
$45.85
Volume
214,392
Avg. Vol
171,658
52-wk High
$62.75
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Zogenix Announces Proposed Public Offering Of 6,000,000 Shares Of Common Stock
Monday, 6 Aug 2018 05:14pm EDT 

Aug 6 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES PROPOSED PUBLIC OFFERING OF 6,000,000 SHARES OF COMMON STOCK.ZOGENIX - INTENDS TO USE PROCEEDS FROM OFFERING TO FUND REGULATORY SUBMISSIONS OF ZX008 FOR DRAVET SYNDROME, AMONG OTHERS.  Full Article

Zogenix Inc Q4 Loss Per Share $1.17
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - Zogenix Inc ::ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.17.QTRLY NET LOSS PER SHARE $1.17.Q4 EARNINGS PER SHARE VIEW $-0.90 -- THOMSON REUTERS I/B/E/S.DUE TO WIND-DOWN OF SUMAVEL DOSEPRO MANUFACTURING OPERATIONS, CO RECORDED NO REVENUE FOR 3 MONTHS ENDED DEC 31, 2017.Q4 REVENUE VIEW $0.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008
Tuesday, 6 Feb 2018 08:00am EST 

Feb 6 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES RECEIPT OF FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IN DRAVET SYNDROME.ZOGENIX INC - FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IS BASED ON RESULTS FROM STUDY 1.  Full Article

Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008
Monday, 4 Dec 2017 08:00am EST 

Dec 4 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - DATA SHOWS ZX008 PATIENTS MORE LIKELY TO ACHIEVE CLINICALLY MEANINGFUL REDUCTION IN SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO.ZOGENIX INC - LOOK FORWARD TO SHARING TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 TRIAL OF ZX008, STUDY 1504, IN Q2 OF 2018.  Full Article

Zogenix Announces Initiation Of Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
Wednesday, 29 Nov 2017 08:05am EST 

Nov 29 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES INITIATION OF PHASE 3 TRIAL FOR ZX008 IN LENNOX-GASTAUT SYNDROME.  Full Article

Zogenix posts Q3 loss of $1.68 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Zogenix Inc :Zogenix provides corporate update and reports third quarter 2017 financial results.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Q3 loss per share $1.68.At September 30, 2017, company had cash and cash equivalents of $64.7 million, compared to $91.6 million at December 31, 2016​.  Full Article

Zogenix prices public offering of common stock
Monday, 2 Oct 2017 08:05pm EDT 

Oct 2 (Reuters) - Zogenix Inc :Zogenix prices public offering of common stock.Priced an underwritten public offering of 6.7 million shares of its common stock at a price to public of $37.50 per share.  Full Article

Zogenix files for potential mixed shelf filing; size not disclosed - SEC filing‍​
Monday, 2 Oct 2017 06:59am EDT 

Oct 2 (Reuters) - Zogenix Inc :Files for potential mixed shelf filing; size not disclosed - SEC filing‍​.  Full Article

Zogenix announces proposed public offering of 4.3 mln shares
Monday, 2 Oct 2017 06:52am EDT 

Oct 2 (Reuters) - Zogenix Inc : :Zogenix announces proposed public offering of 4,300,000 shares of common stock.Zogenix Inc - ‍intends to use net proceeds from proposed offering to fund clinical research and development of zx008​.  Full Article

Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome
Friday, 29 Sep 2017 07:00am EDT 

Sept 29 (Reuters) - Zogenix Inc : :Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome.Zogenix Inc - ZX008 also demonstrated statistical significance in all key secondary endpoints.Zogenix Inc - ‍primary endpoint was achieved.Zogenix Inc - ‍expect top-line results from second pivotal phase 3 trial, study 1504, which is nearing full enrollment, in first half of 2018​.Zogenix Inc - ‍ZX008 was generally well-tolerated in study.Zogenix Inc - remain on track to submit applications for regulatory approvals in U.S. And Europe in second half of 2018.  Full Article

Photo

Zogenix's seizure drug clears late-stage trial, shares soar

Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.